Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives.
Malmberg R, Agema BC, Hofman MM, Oosterveld S, Bins S, Dumoulin DW, Joosse A, Aerts JGJV, Debets R, Koch BCP, van der Veldt AAM, van Leeuwen RWF, Mathijssen RHJ.
Malmberg R, et al. Among authors: van leeuwen rwf.
Cancer Commun (Lond). 2025 Apr;45(4):471-475. doi: 10.1002/cac2.12661. Epub 2025 Jan 16.
Cancer Commun (Lond). 2025.
PMID: 39817458
Free PMC article.
No abstract available.